EPA:AB - Euronext Paris - Matif - FR0010557264 - Common Stock - Currency: EUR
EPA:AB (3/21/2025, 7:00:00 PM)
1.39
-0.01 (-0.57%)
The current stock price of AB.PA is 1.39 EUR. In the past month the price increased by 4.35%. In the past year, price decreased by -45.17%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1LLY.MI | ELI LILLY & CO | 63.87 | 727.34B | ||
LLY.DE | ELI LILLY & CO | 62.98 | 717.20B | ||
ZEG.DE | ASTRAZENECA PLC | 18.36 | 431.41B | ||
JNJ.DE | JOHNSON & JOHNSON | 16.31 | 362.44B | ||
NOV.DE | NOVO NORDISK A/S-B | 23.52 | 316.42B | ||
1SAN.MI | SANOFI | 13.99 | 269.42B | ||
SNW.DE | SANOFI | 13.78 | 265.41B | ||
SAN.PA | SANOFI | 13.78 | 265.36B | ||
1MRKX.MI | MERCK & CO. INC. | 12.27 | 218.76B | ||
6MK.DE | MERCK & CO. INC. | 12.25 | 218.50B | ||
PFE.DE | PFIZER INC | 8.46 | 137.66B | ||
1PFE.MI | PFIZER INC | 8.39 | 136.41B |
AB Science SA operates as a pharmaceutical company, which engages in the research, development, and marketing of synthetic therapeutic molecules for pathologies with high medical need, in diseases of the central nervous system, cancers, and inflammatory diseases. The company is headquartered in Paris, Ile-De-France and currently employs 45 full-time employees. The company went IPO on 2010-04-21. The company is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine. The main focus of the Company is the development of tyrosine kinase inhibitors, for instance Masitinib which is a tyrosine kinase inhibitor used as a veterinary medicine in the treatment of canine mast cell tumors. The firm is present in the United States and Europe. As of December 31, 2013, the Company operated though a subsidiary, AB Science USA LCC, based in the United States.
AB SCIENCE SA
3 avenue George V
Paris ILE-DE-FRANCE FR
Employees: 54
Company Website: https://www.ab-science.com/
Investor Relations: http://www.ab-science.com/investors/regulated-information/annual-financial-reports/
Phone: 33147200014
The current stock price of AB.PA is 1.39 EUR. The price decreased by -0.57% in the last trading session.
The exchange symbol of AB SCIENCE SA is AB and it is listed on the Euronext Paris - Matif exchange.
AB.PA stock is listed on the Euronext Paris - Matif exchange.
9 analysts have analysed AB.PA and the average price target is 3.5 EUR. This implies a price increase of 151.7% is expected in the next year compared to the current price of 1.39. Check the AB SCIENCE SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AB SCIENCE SA (AB.PA) has a market capitalization of 80.38M EUR. This makes AB.PA a Micro Cap stock.
AB SCIENCE SA (AB.PA) currently has 54 employees.
AB SCIENCE SA (AB.PA) has a support level at 1.38 and a resistance level at 1.4. Check the full technical report for a detailed analysis of AB.PA support and resistance levels.
The Revenue of AB SCIENCE SA (AB.PA) is expected to grow by 37.5% in the next year. Check the estimates tab for more information on the AB.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AB.PA does not pay a dividend.
AB SCIENCE SA (AB.PA) will report earnings on 2025-05-13.
AB SCIENCE SA (AB.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).
ChartMill assigns a technical rating of 5 / 10 to AB.PA. When comparing the yearly performance of all stocks, AB.PA turns out to be only a medium performer in the overall market: it outperformed 59% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to AB.PA. Both the profitability and financial health of AB.PA have multiple concerns.
Over the last trailing twelve months AB.PA reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 66.19% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -26.29% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 87% to AB.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -20.59% and a revenue growth 37.5% for AB.PA